ERBB2 and breast carcinoma: Although targeted treatment with anti-HER2 agents has significantly improved the disease-free and overall survival rates of metastatic and early-stage HER2-positive breast cancer patients[8-11], resistance to anti-HER2 therapy, both primary and acquired, has emerged as a major clinical problem in the treatment of HER2-positive breast cancer patients[12-14].